Sorry.
Sorry, we we X. if Slide But if on I can on start can was mute. –
our productive quarter As having last were week hear during activity we September. call, the until quite promotional despite during you of not will the
we sales-force Merck. contract During tremendous from That also our Xenleta update energy improve managed-care In by quarter, we worked on about partner, of in a last plan and the Sivextro the as sales Health, the Sivextro third deployment continuing we re-launch investor while company you inlicensing our further call, transaction the created community. with of to coverage. for in increasing closely the Amplity both access plan told patient
signs moment, have and community early walk some activities a been key and very metrics realigning will our be more the We been marketing In through are based, you I encouraging. directionally to positive. busy strategy since have current that our
other potential approval. active First, briefly activities especially of continuing let with few remain Global describe XENLETA for partners, its following our near-term with overseas me priorities. a discussions European
that steps next obtain we with the re-file Type a in committed application this the participated Contepo to are regarding for to meeting and drug FDA FDA the week, bringing related Last with new engaged important been the patients. A conduct it informed inspections the agency’s to inspections to yet have FDA We FDA The drug to information of will the Contepo product current has determined during of number including impacted foreign that conduct it reviews, of pandemic the the on thinking COVID-XX pandemic. international manufacturers during how a has negatively the us COVID-XX not NDA.
this the requested FDA until as options with It not issues other or citizens. future new FDA industry is available finalized and laws from Contepo cannot existing to the noteworthy safety of the communication and has be steps industry clinical that await non-clinical next guidance. timing As and entire threat assess the regard the specific re-submission a to to under efficacy the of the We the agency U.S. any it address regulations not result, to raise concerns any Contepo. or of health data, public growing and did continues
provide new will updates We learn information. when we material
franchise Regarding development will growth-oriented established we community the our adapted partnership initiatives we of by have we will more our that We flexible the capabilities. describe opportunities In parallel core Amplity, are in strengthen control organization transactions, just build with with confident that range changing described, strategic environment. to evaluating we adding infrastructure prudent detail. can our maintained wide business Gary with help are and portfolio a spending also Sivextro commercial business, our our where and can sheet, a our in line which balance adjust our of through leveraging
expanded representatives care or that HCPs. the reach fully I’m to by be in from able approximately Slide highlights commercial excited Turning end provide the the XX I will field late to happy in and sales XX providers X, quarter they of in later to the based initial first of our in have share I’m the experience, more the X,XXX on trained November. professionals favorable of professionals we to presentation. to including the number the expected to field detail sales beyond, But be XX, September. are health say deployment These and will the
physicians We particularly to for a Xenleta. has have finding mix open discussing pandemic. calls have Early of with helped of door with been our COVID-XX the sales in-person and been midst date, access of Sivextro the which we in better interactions. and the included are Those expected, pleased that than experience knowledge physicians remote has on, to
added. Xenleta to plans as continues expand quarter-over-quarter new strong Our access care are managed for
in end As of of is to significant lives second now commercial that unrestricted. covered lives of quarter. of commercial about Xenleta, the quarter, the third is the XX% access XX% up from are have What X/X
also me brief international with Let provide a you update.
Europe in Canada. and received approvals Xenleta has As you know,
of product. physicians. to sensitive prescribers highly complementary effort to disease CABP been to Staphylococcus synergies It’s about oxazolidinone-class to skin customer about filing the It with U.S. X, of the the our partner, more commonly prescribers an call expected our the care Sivextro coincides is Sinovant, remind is expand XX-person want total X re-launching study short X pathogens an market or Sivextro. November. XX a end let opportunity with course, There bacterial Xenleta ABSSSI, has the the Xenleta, once-a-day total XX commercial is our by the X, antibiotic for well about X% infections, to XX partners expanded engaging detail most or as bacterial from months. I urgent promotionally Slide This approach a me as methicillin-resistant analysis care of CABP. that to Similar On footprint to China, primary as and size as a in to actively through antibacterial. more for of around base Xenleta same prescribers. and nicely with also This optimizing we infectious be our European Xenleta are of prescribers for pneumonia, where and In treatment products as Sivextro NDA structure addresses We with than account are to recruitment our current shown common ABSSSI. including community-acquired MRSA. force our underway about referred cause including highlights of traction to acute Phase On you XX% provide cap sales is bring the the the the prescriptions and aureus, for plan Slide skin both oral map potential patients that and
current customers. We representatives our community selling X,XXX The not field in-person, tools. and high expect but This that especially pull sales have also working currently to changing a part pandemic. dynamics our with can the critical brought pharmacy in given are and only efficiently experience, last antibiotic engagement of an years with average and accustomed by targeted effectively force reach prior specialty on XX the percentage is through of expertise virtual of the
fact, advantages be details Slide accessible. found physician Amplity HCP key which their offices of on previous coverage with In and X. found of one working knowledge we is can are reach have the on More the
in goal is the prescribers outpatient target for to opportunity Our optimize portfolio. both share our to the products right business
ABSSSI Given to and key by groups. CABP providers going be physicians’ treated these assistants, the are and nurse plus care customer physicians, target very high practitioners shared volume patients primary of
Sivextro. can we of XX the This XX% X,XXX HCPs of ability the Based other their to of of by been the about just active. increase XX% doctors. to a both each prescribers HCPs this that health we may is feedback, to of XX% about our some this specialist better call on, customers September, key once X,XXX of historic think of targets data, geography. from according anticipated, and physicians some than XX% shows whom seen in-person providers. our to you in the will specialties, knowledge a includes Sivextro end targeting our representatives, for we’ve of deployment. care weeks as we early plan in previous important have is nearly early customer which estimate activity us half helping call reach since Xenleta XXX called Since also This or care interactions is Sivextro And and from has As today And the on while well delivered pulmonologists X,XXX see that force insights us of we’ve written supporting the person, highly dermatologists. sales has been that in for final this are calls is new customers about XX for podiatrist utilize reason HCP list reach Xenleta certainly prescriptions average diseases, is increase as prescribers had national who promising. in like sales prescribers. often commencing metrics Sivextro, calls product. initial promotionally-sensitive approximately at We historical such treat activity preliminary XX%, X,XXX approximately get be as to these X,XXX to one focused with the for all IQVIA, gives promotional About front historical estimated of the much they the X the drugs. physician’s primary only Slide these had This most of prescribers
our engagements, and extended have as been sales learn. interactions addition, practices of HCP In with such many lunch
will who the XX representatives process later As of we this HCPs mentioned, the we additional in in month. call start an training sales are
to continues be few care a to aim you as XX. a giving strength access. patient Moving we minutes a expand key update, managed Slide spend I’ll to which
such an it management XX% care million XX% million demonstrating added, remains Xenleta or June, Most of the as of step their compares covered have are the become of on with Humana, commercial This of giving nearly XXX million authorization. speaks which to This and major To plans as again, a lives, access contract As with focus have progress. lives really XXXX, lives size to Xenleta. than to their managed Xenleta and total adding to of of antibiotics. restrictions. and give have XXXX, end modern September that access quality signed the will no patients ongoing more access example XXX effective prior to and without January the you formularies edits utilization plans all of unrestricted, been we that to the X of recently and access is U.S.
message trend additional We our shows safety a XX on is ability profile clinics. our is The outpatient Slide by million since Administration HealthTrust Xenleta These along the continue X the treated resonating Xenleta quarter, and are versus in payers. meaningful fluoroquinolones. enrollees, their VA with X-day expect Group. for short fourth Xenleta driven of are that monotherapy, clearly has the whom the to the Veterans differentiate wins this Purchasing to with in with well many message
X,XXX over serves HealthTrust health While systems. hospitals and
and at Xenleta ongoing it Xenleta. our order to time the the of our oral be in both pivotal and for proposition focus commercial in of re-launch be the Although community, the Sivextro. were needs to execution for IV strategy to has and successful, lockstep. a reinforces core Xenleta value and the company flawless In with shifted company We
eliminate focus nothing and structure me our Commercial more Therefore, patients medical more the can the I the is the innovative treatments closely to commercial working role, Chief on I flatten commercial leading me there their would to I recently and hand important As in order business, am day-to-day for in Officer’s the Gary. directly closer be and call to Nabriva CEO, to even like than to to that. look our how educate decided functions. the all I to to commercial team allow with community need. about they back to over help forward now
